ersatile Restylane hyaluronic acid (HA) injectable range in the face will also be presented.7.8Restylane Lyft™ demonstrated noninferiority to a comparator HA injectable for chin profile improvement at Month 3, and sustained aesthetic improvement and subject satisfaction through Month 12.7Meanwhile, Restylane Volyme™ was shown to be well tolerated and effective for correcting temple hollowing, delivering high and longlasting aesthetic results through Month 18 alongside strong patient satisfaction.8

Empowering clinicians with evidence-based guidance for increasingly complex patient profiles
At the congress, Galderma will share insights into complex patient profiles, including findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, such as wrinkles, loss of firmness, dryness and dull skin, and the growing relevance of aesthetic treatments in addressing these concerns.9

This, and other complex
=*=*=*=*=*=
当前为第6/20页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页